Short-term outcomes of COVID-19 and risk factors for progression
Long Li, Xiansheng Zeng, Xu Zhang, Wei Xiao, Ensong Guo, Wenzhi Zhan, Xuejiao Yang, Chunyan Li, Caiyun Wu, Tingting Xu, Chen Zhan, Yuehan Chen, Mei Jiang, Nanshan Zhong, Kefang Lai
Abstract
<b>With a median (IQR</b><b>) follow-up time of 24.0 (17.5–30.0) days, progression occurred in 19.6% moderate, 27.8% severe and 66.7% critical COVID-19. Neutrophil-to-lymphocyte ratio ≥2.973, age ≥50 years, male sex and comorbidity were associated with progression.</b>https://bit.ly/3crsJr0
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)ComorbiditySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakInternal medicinePathologyDiseaseInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19COVID-19 and healthcare impacts